公开(公告)号：US20170176432A1

公开(公告)日：2017-06-22

申请号：US14905621

申请日：2014-01-17

Applicant: OSAKA UNIVERSITY

Inventor： Hisashi ARASE ,  Kenji TANIMURA ,  Hui JIN ,  Noriko ARASE

IPC: G01N33/564 ,  G01N33/569

CPC classification number: G01N33/564 ,  G01N33/56977

Abstract: The present invention provides an autoantibody detection method that can detect an autoantibody causing an autoimmune disease with high accuracy. The autoantibody detection method of the present invention includes the steps of; causing a sample and an antigen reagent comprising a denatured protein presented by an MHC class II molecule to come into contact with each other; and detecting a complex of an autoantibody in the sample and the denatured protein in the antigen reagent. By detecting a complex of the autoantibody and the denatured protein in a biological specimen isolated from a subject according to this detection method, it is possible to test the possibility of the autoimmune disease in the subject from the detection result.

公开(公告)号：US20210187002A1

公开(公告)日：2021-06-24

申请号：US16767929

申请日：2018-11-28

Applicant: OSAKA UNIVERSITY

Inventor： Hisashi ARASE ,  Fumiji HIRAYASU ,  Kouyuki HIRAYASU

IPC: A61K31/7088 ,  G01N33/15 ,  C07K14/445 ,  C07K14/705 ,  A61P33/06

Abstract: The present invention provides a new antimalarial drug. The antimalarial drug of the present invention includes: a binding inhibitor that inhibits binding between a RIFIN protein and a leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) protein; an inducer of the binding inhibitor; or an expression inhibitor of RIFIN or LILRB1.

公开(公告)号：US20180064792A1

公开(公告)日：2018-03-08

申请号：US15563337

申请日：2016-03-30

Applicant: OSAKA UNIVERSITY

Inventor： Hisashi ARASE ,  Kazuki KISHIDA

IPC: A61K39/00 ,  A61K39/35 ,  A61K39/39 ,  C07K16/28 ,  C07K14/47 ,  C07K19/00

Abstract: The present invention provides a novel immunizing peptide that can induce production of an antibody to a complex of the immunizing peptide and an MHC molecule of a living organism The immunizing peptide according to the present invention includes a T-cell epitope and an antibody-inducing portion of a target protein. The antibody-inducing portion is at least one of the following amino acid residues in an amino acid sequence of the target protein: one or more contiguous amino acid residues immediately upstream of a N-terminal amino acid residue of the T-cell epitope; and one or more contiguous amino acid residues immediately downstream of a C-terminal amino acid residue of the T-cell epitope. When the immunizing peptide is administered to a living organism, the immunizing peptide induces production of an antibody to a complex of the immunizing peptide and an MHC molecule of the living organism.